Rxo (RXO) Operating Expenses (2021 - 2026)

Rxo has reported Operating Expenses for 6 years, with the latest figure at $197.0 million in Q1 2026.

• For the quarter ending Q1 2026, Operating Expenses fell 6.19% year-over-year to $197.0 million; the trailing twelve-month figure through Mar 2026 stood at $819.0 million (up 12.04% YoY), and the FY2025 full-year result was $832.0 million, up 24.92% from the prior year.
• Operating Expenses for Q1 2026 stood at $197.0 million, down from $200.0 million in the prior quarter.
• The five-year high for Operating Expenses was $218.0 million in Q4 2024, with the low at $144.0 million in Q2 2023.
• Historically, Operating Expenses has averaged $172.1 million across 5 years, with a median of $158.0 million in 2022.
• Annual changes were most pronounced in 2023 — Operating Expenses slipped 13.25% — and 2024, when it jumped 49.32%.
• Rxo's Operating Expenses stood at $155.0 million in 2022, then slipped by 5.81% to $146.0 million in 2023, then jumped by 49.32% to $218.0 million in 2024, then retreated by 8.26% to $200.0 million in 2025, then fell by 1.5% to $197.0 million in 2026.
• The last three Operating Expenses figures came in at $197.0 million (Q1 2026), $200.0 million (Q4 2025), and $208.0 million (Q3 2025), per Business Quant data.